Epidermolysis bullosa acquisita and neuroendocrine pancreatic cancer - Coincidence or patho-genetic relationship?
J Dtsch Dermatol Ges. 2007 Oct;5(10):916-8.
doi: 10.1111/j.1610-0387.2007.06338.x.
[Article in
English,
German]
Affiliation
- 1 Clinic for Dermatology, Venerology and Allergology, University Dermatology Clinic, Kiel, Germany. obusch@dermatology.uni-kiel.de
Abstract
The etiology of epidermolysis bullosa acquisita (EBA) is unknown. EBA may be associated with other autoimmune systemic diseases; it also has been described in connection with different malignant tumors, showing complete remission after successful treatment of the tumor. In such cases, EBA may be regarded as a paraneo-plastic dermatosis. We detected a highly differentiated neuroendocrine pancreatic cancer in a 78-year-old woman with EBA. Even thought her tumor was completely removed and the patient has been disease-free for over seven years, a complete regression of her autoimmune bullous dermatosis could not be induced. By using intravenous immunoglobulins in combination with mycophenolate mofetil, further blister formation could be ameliorated.
MeSH terms
-
Aged
-
Anti-Inflammatory Agents / administration & dosage
-
Antibiotics, Antineoplastic / administration & dosage
-
Carcinoma, Neuroendocrine / complications*
-
Carcinoma, Neuroendocrine / diagnosis
-
Carcinoma, Neuroendocrine / drug therapy*
-
Carcinoma, Neuroendocrine / genetics
-
Epidermolysis Bullosa Acquisita / complications*
-
Epidermolysis Bullosa Acquisita / diagnosis
-
Epidermolysis Bullosa Acquisita / drug therapy*
-
Epidermolysis Bullosa Acquisita / genetics
-
Genetic Predisposition to Disease
-
Humans
-
Immunoglobulins / administration & dosage*
-
Male
-
Mycophenolic Acid / administration & dosage*
-
Pancreatic Neoplasms / complications*
-
Pancreatic Neoplasms / diagnosis
-
Pancreatic Neoplasms / drug therapy*
Substances
-
Anti-Inflammatory Agents
-
Antibiotics, Antineoplastic
-
Immunoglobulins
-
Mycophenolic Acid